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Several unique features characterize infectious disease epidemiology in
New Zealand. Historically, well-organized, government-run control pro-
grams have eliminated several zoonoses. More recently, however, commu-
nicable disease control has been mixed. Rates of rheumatic fever,
tuberculosis, and enteric infections are high, and rates of meningococcal
disease are increasing. These diseases are overrepresented in New
Zealanders of Polynesian descent, who generally live in more deprived and
overcrowded conditions than do those of European descent. Measles and
pertussis epidemics are recurring because of inadequate vaccine coverage,
despite a well-developed childhood immunization program. A progressive
response to the HIV epidemic has resulted in relatively low rates of infec-
tion, particularly among injecting drug users; however, the response to other
sexually transmitted infections has been poor. A key challenge for the future
is to build on successful strategies and apply them to persisting and emerg-
ing infectious disease threats in a small, geographically isolated country
with limited economic resources.
Unique Historical and Epidemiologic Features
New Zealand (known as Aotearoa in Maori), a South
Pacific nation with a population of 3.8 million, is the largest
island group in Polynesia (Figure). It shares strong biologic
similarities with other islands in Polynesia, although it is
often wrongly grouped with Australia. New Zealand has sev-
eral unique features of special interest in the study of emerg-
ing infectious diseases. These include unusual native fauna,
lack of native terrestrial mammals, and recent incursions of
exotic fauna. With exotic fauna came a limited range of
zoonoses that were successfully controlled and excluded by a
strict quarantine system. Furthermore, New Zealand has
unusually high rates of some endemic infectious diseases
and delayed impact from infectious diseases emerging in
other parts of the globe. 
New Zealand developed from the margin of the southern
landmass of Gondwana. Separation from Australia and Ant-
arctica occurred 100 to 75 million years ago (1). The country
is one of the most geographically isolated and remote tem-
perate islands in the world. Until recently, this isolation
allowed a peculiar native fauna to evolve in the absence of
natural predators and incursions by exotic species. The only
native mammals of New Zealand are two genera of bats
(Chalinolobus spp. and  Mystacina spp.). Native bird and
insect species evolved to fill ecologic niches that in other
countries are occupied by mammalian species. Native para-
sitic arthropods matched the limited range of terrestrial
fauna. It is thought that relatively few microorganisms capa-
ble of infecting humans existed in New Zealand before the
arrival of the first settlers.
The first evidence of humans in New Zealand dates to
approximately 700 years ago. The colonizing Polynesian pop-
ulation is now known as the Maori. Strong oral and artistic
traditions maintained by the Maori are not particularly
revealing of early health history.
Figure. New Zealand and the region of Polynesia.
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European exploration began in 1642 and continued until
1769. Introduced epidemic disease occurred among the
Maori population from the 1790s. The introduction of infec-
tious agents such as Influenza virus (2) parallels similar
introductions elsewhere in the world. Colonization, prima-
rily from Great Britain, followed in the 1790s. Migrants
brought a range of infectious diseases endemic in Europe.
New Zealand’s native fauna does not include recognized
intermediate hosts for human pathogens. The introduction of
exotic terrestrial mammals created a new potential for
zoonotic disease. In the 14th century, early Polynesian immi-
grants introduced the Polynesian rat (Rattus exulans) and,
much later, the dog. However, the arrival of Europeans with
a vast range of exotic species 200 years ago brought about
one of the most massive recent introductions of new species
into a virgin environment.
British explorer Captain James Cook introduced pigs
(Sus scrofa) and goats ( Capra hircus) to New Zealand in
1773. The brown rat (R. norvegicus), the black rat (R. rattus),
and the house mouse (Mus musculus) were introduced 150 to
200 years ago. Various animals followed, including hedge-
hogs (Erinaceus europaeus), three species of the genus Mus-
tela (stoat, weasel, and ferret), various species of deer
(including  Dama dama), chamois ( Rupicapra rupicapra),
thar (Hemitragus jemlahicus), hares (Lepus europaeus), rab-
bits (Oryctolagus cuniculus), wallabies (Macropus sp.), and
the Australian brush-tailed possum (Trichosurus vulpecula).
In addition, domestic animals, including cats, cattle, sheep,
and horses, were introduced (3,4).
Along with exotic fauna came a variety of ectoparasites,
some of which were potential vectors for arthropod-borne
disease. These included the dog flea (Ctencephalides canis),
the cat flea (C. felis felis), the human body louse (Pediculus
humanus) and various animal louse species, several culicine
mosquito species (including Aedes notoscriptus, A. australis,
and Culex quinquefasciatus), a limited number of tick spe-
cies (including  Ixodes holocyclus), and the oriental rat flea
(Xenopsylla cheopis) (5).
Several factors limited the range of zoonoses introduced
to New Zealand. These included a small number of animal
sources (almost exclusively from the British Isles, Australia,
and Chile) and the selection of only healthy stock for trans-
portation. Although settlement and trade often came via
Australia, the extended sea voyage to New Zealand during
the early European period provided a form of enforced quar-
antine for some diseases (3,6). Only diseases that could per-
sistently circulate in the crowded conditions of these voyages
and those that persisted in a chronic state in humans or ani-
mals were imported. The opportunity to take advantage of
an island free of most mammalian diseases was recognized
by agriculturalists and government, and strict quarantine
practices were rapidly put in place. Since primary production
has been the main contributor to New Zealand’s economy,
there is a strong interest in preventing the importation of
animal diseases, many of which are potential zoonoses. New
Zealand maintains one of the most strict quarantine systems
in the world.
This system has been highly successful but has not been
immune to biocriminal acts, such as the illegal importation
of Rabbit hemorrhagic disease virus, probably from Austra-
lia, first detected in New Zealand in August 1997. In the
absence of natural predators, rabbits thrive in New Zealand
and cause considerable damage to grazing pasture. The
covert introduction of this rabbit virus appears to have been
motivated by frustration among farmers. Although this bio-
security breach has not had detectable consequences for
human health, it illustrates the potential for agents to
escape even the most vigilant quarantine systems (7).
Emergence and Control of Zoonotic Diseases
With the early importation of exotic animals came a lim-
ited but important range of zoonotic diseases. These diseases
emerged over the past century with the development of an
agriculture-based economy. At its peak in the 1980s, New
Zealand had 27 production farm animals per capita.
Although this figure has fallen to approximately 18 per cap-
ita, the occupational hazards for zoonotic disease in New
Zealand agricultural workers are higher than in countries
where similar diseases occur but the ratio of humans to ani-
mals is lower (3). New Zealand has been successful in the
control and elimination of some zoonoses; however, others
remain problematic.
The threat of introducing plague from the infested ports
of post-penal Australia led to the establishment of the New
Zealand Department of Health in the late 1800s. Despite
improved quarantine, plague did become established in New
Zealand as an epizootic of rats in 1900. Human cases
occurred from June 1900 until May 1911. Most cases
occurred in Auckland, and only one occurred in South Island
at the port of Lyttelton. The disease was controlled by a
strict port health inspection system, surveillance of arrivals,
fumigation of luggage, rat surveillance, and improved build-
ing sanitation. Spread was also minimized as the result of
low human population density (8).
Anthrax was introduced into New Zealand in the mid-
1890s from Calcutta in unsterilized bone dust fertilizer. Out-
breaks declined when public health workers, whose infra-
structure had been strengthened by the plague effort,
imposed sterilization regulations on imported bone dust. The
last case of anthrax was recorded in New Zealand in 1954. It
is believed that anthrax spores and bacilli are unlikely to
persist in New Zealand soils because of high competitive
microbial activity (6). As a precaution, several properties
remain under active surveillance for the disease.
Historically,  Brucella abortus was endemic in New
Zealand cattle herds and was an important occupational
pathogen in farmers and animal slaughterers. A successful
animal vaccination and surveillance system resulted in the
last indigenous bovine case of brucellosis in New Zealand in
1989; no further indigenous human cases have been recorded
(9). B. suis and B. melitensis are absent from New Zealand,
and Francisella tularensis is believed to be absent.
Echinococcosis was probably well established in New
Zealand before 1873, when it became notifiable. Annual
human incidence reached 7 per 100,000 persons between
1900 and 1925. The risk for disease was five to six times
higher for New Zealanders of Polynesian descent. Arecoline
hydrobromide was introduced in 1908 for treatment of dogs,
and an official education program began in 1938. Neither
intervention affected the incidence of hydatid disease. In the
late 1950s, a massive national effort was undertaken, includ-
ing the establishment of 800 local voluntary committees
throughout New Zealand, education, promotion, peer pres-
sure, dedicated “hydatids officers,” and the introduction ofPerspectives
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the Hydatids Act of Parliament that imposed a levy on dog
owners and compulsory dog registration. Canine-stool sur-
veillance and use of arecoline continued until 1972, when it
was combined with niclosamide treatment (administered
every 6 weeks) and, in 1978, praziquantel. By 1990, active
surveillance showed that only three farms were still not free
of Echinococcus granulosus. In 1999, New Zealand was pro-
nounced provisionally free of hydatids. Human cases of
hydatid disease now represent distant past infection, and
the New Zealand hydatid control program has been widely
regarded as a success (10).
Leptospirosis is endemic in New Zealand and is a fre-
quent cause of disease in farmers and meat workers (11). Of
more than 180 recognized serovars of Leptospira, only 8 have
been isolated in New Zealand. These are L. interrogans sero-
vars australis, canicola, copenhageni, and  pomona, and  L.
borgpetersenii serovars  balcanica, hardjobovis, tarassovi,
and ballum. Of these, serovars australis and canicola have
been isolated only once each, probably reflecting imported
disease in the absence of an endemic animal reservoir. Sero-
vars hardjobovis, pomona, and tarassovi account for >90% of
human leptospirosis cases in New Zealand. Approximately
two thirds of disease in dairy farmers is due to serovars
hardjobovis and one third to serovar pomona. Swine farmers
are more often infected with serovars pomona and tarassovi.
A readily available animal vaccine, combined with improved
milking facilities and sanitation, has contributed to a reduc-
tion in human cases. The ongoing annual incidence rate of
leptospirosis of 5 per 100,000 persons probably reflects
underuse of the animal vaccine. Although serovar balcanica
is maintained in the possum, transmission of balcanica from
possums to production animals appears uncommon.
Mycobacterium bovis disease is now rare among New
Zealanders, partly because of pasteurization of dairy prod-
ucts. However, the elimination of M. bovis from cattle herds
has proved difficult despite widespread efforts by the veteri-
nary community. New Zealand’s maligned Australian brush-
tailed possum population, estimated at approximately 70
million, emerged as a sylvatic M. bovis reservoir in the 1970s
and provided a major source of transmission to cattle and
deer. Cattle herds in regions of endemic disease are kept
under movement control, and a “test and slaughter” policy is
in place. The prospect of eliminating animal disease is
daunting.
Several zoonotic diseases are notable by their absence. Q
fever has been carefully sought for but never found in New
Zealand (12). The absence of the disease despite large ani-
mal herds, a large farming community, and high levels of
animal slaughter is a tribute to careful quarantine, lack of
an efficient arthropod vector, and probably an element of
good fortune. New Zealand is free of bovine spongiforme
encephalopathy because of strict control of animal feed and
animal importation. Rabies is also absent from New
Zealand, probably reflecting the prolonged duration of the
early sea voyage, which exceeded its incubation period in
animals; the paucity of indigenous biting animals in the
early colonial period; and subsequent strict quarantine prac-
tices.
Endemic and Epidemic Infectious Diseases 
The control of infectious diseases in New Zealand during
the 1980s and 1990s has been mixed, characterized by per-
sisting and emerging threats, as well as successes and fail-
ures (Table). 
Infectious Diseases of Poverty and Overcrowding
Certain endemic bacterial diseases have emerged as
major causes of illness and death, particularly among New
Zealanders of Polynesian descent. These are focused around
Table. Key infectious disease threats facing New Zealand
Infectious 
disease category Important examples
Contributing 
factors
Vaccine-
preventable 
diseases
Measles
Pertussis
Influenza
Inadequate 
vaccine coverage
Respiratory-
transmitted 
diseases
Meningococcal disease
Tuberculosis
Rheumatic fever
Socioeconomic 
deprivation and 
crowding
Enteric diseases Campylobacteriosis
Salmonellosis
Cryptosporidiosis
Shiga toxin-producing 
Escherichia coli
Yersiniosis
Marine biotoxins
High density of 
reservoir animals
Long coastline (in 
the case of marine 
biotoxins)
Zoonotic disease Leptospirosis High levels of 
infection in 
animal 
populations
Diseases from 
contaminated 
environments
Legionellosis Uncertain
Travel-
associated and 
imported 
infectious 
diseases
Hepatitis A
Tuberculosis
HIV/AIDS
High rates of 
overseas travel
Relatively high 
levels of 
immigration
Vector-borne 
diseases
Ross River virus
Dengue virus
Suitable vector 
mosquitoes and 
potential NZ 
habitats
Blood-borne 
diseases
Hepatitis C Continuing 
sharing of 
injecting 
equipment by 
injecting drug 
users
Sexually 
transmitted 
infections
Chlamydia
Gonorrhea
Increased levels of 
sexual activity 
among young 
people
Hospital-
acquired 
infections
MRSA
Acinetobacter spp.
Serratia spp.
Disease burden 
poorly defined in 
NZ and no 
national HAI 
surveillance 
system
Diseases caused 
by antibiotic-
resistant 
organisms
Penicillin-
nonsusceptible 
pneumococci
VRE
MDR-TB
Microbial 
evolution and 
incorrect use of 
antimicrobial 
agents
Abbreviations used in this table: NZ, New Zealand; HAI, hospital-acquired
infection; MRSA, methicillin-resistant  Staphylococcus aureus; VRE, van-
comycin-resistant enterococci; MDR-TB, multidrug-resistant tuberculosis.Perspectives
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urban south Auckland and rural parts of North Island,
where populations live under difficult socioeconomic condi-
tions.
A serogroup B meningococcal disease epidemic began in
1991 and has persisted for >10 years. Disease rates exceed
12 per 100,000 persons per year, well above those in other
industrialized countries (13). Household crowding is an
important risk factor, at least for children (14). Identification
of the epidemic strain as phenotype B:4:P1.4 provides the
opportunity to test the efficacy of a strain-specific serogroup
B meningococcal vaccine (15).
After declining for many decades, tuberculosis rates
reached a plateau during the 1980s and began to rise during
the 1990s. In 1999, 450 cases were reported (12.4 per
100,000), the highest incidence for 20 years (16). Rates
among New Zealanders of Polynesian descent are 5 to 15
times higher than among persons of European descent.
Immigration from other areas in Oceania (Australia and the
Pacific Islands) and high-incidence countries accounts for
approximately half the cases each year.
Group A streptococcal disease and its complications are
also overrepresented in New Zealanders of Polynesian
descent. An average of 100 initial attacks of rheumatic fever
have been reported annually in New Zealand over the past
10 years (17). The contributions of environmental and bio-
logic determinants are yet to be established, but there is evi-
dence that both may play a role. Improved management of
group A streptococcal disease and secondary prophylaxis for
rheumatic fever are research priorities and areas in which
New Zealand has special expertise.
Staphylococcal disease is also overrepresented in New
Zealanders of Polynesian descent. A recent study of Staphy-
lococcus aureus bloodstream infections in Auckland and
Christchurch found a rate of community-acquired S. aureus
bacteremia of 10 per 100,000 per year. Compared with the
risk for infection in persons of European descent, the relative
risk was 1.8 for indigenous New Zealanders of Polynesian
descent (Maori) and 4.0 for nonindigenous New Zealanders
of Polynesian descent (18).
Diseases from Contaminated Environments
Legionella infection is an endemic cause of pneumonia,
at least in South Island (19), and accounts for 10% of hospi-
tal admissions for community-acquired pneumonia. Cases
are generally sporadic, and illness is due to various species
of Legionella.
Vaccine-Preventable Diseases
New Zealand has a well-developed childhood immuniza-
tion program, including universal infant hepatitis B immu-
nization and a two-dose measles, mumps, and rubella
schedule. However, coverage levels remain low, with barely
60% of children fully immunized by the age of 2 years (20).
Consequences include recurring measles (21) and pertussis
epidemics (22). Hepatitis B has been overrepresented among
those of Polynesian descent (23); hepatitis B surface antigen
positivity rates in this population are approximately 5%,
compared with 0.5% in New Zealanders of European
descent. Annual influenza epidemics, which usually peak
around July, also have a large health impact. Free annual
vaccination has recently been introduced for those ‡65 years
of age and those with chronic medical conditions. However,
influenza vaccine coverage remains at only 55% in this age
group (24).
HIV and Other Sexually Transmitted Infections
New Zealand, like Australia, adopted a very progressive
response to the arrival of HIV infection and introduced rou-
tine control measures early in the epidemic. As a conse-
quence, the prevalence of HIV infection has remained
relatively low, particularly among injecting drug users (25).
Most cases of HIV/AIDS are in men who have sex with men.
The response to other sexually transmitted infections has
been far less adequate; consequently, rates of gonorrhea and
chlamydia infection appear to be rising (26).
Enteric Diseases
Enteric infectious diseases rates in New Zealand are
among the highest in industrialized countries (27). Culture-
confirmed campylobacteriosis occurs at a rate of 305 per
100,000 per year and Yersinia enterocolitica at a rate of 14
per 100,000 per year. Furthermore, febrile blood transfusion
reactions due to Y. enterocolitica occur at the rate of 1 per
65,000 transfusions, reflecting the high number of blood
donors with occult bacteremia. These infections occur
despite implementation of guidelines to prevent yersiniosis
arising from transfused blood (28). Salmonellosis also occurs
at relatively high rates in New Zealand. However, the global
pandemics of Salmonella Enteritidis and Salmonella Typh-
imurium DT104 have not emerged in New Zealand. It is
likely that they have been excluded by quarantine practice
on animals and animal feed. Giardiasis and cryptosporidio-
sis (29) rates are also very high. The high rates of endemic
enteric infections are not fully understood. The high ratio of
domestic production animals to humans and frequent use of
rural water supplies in New Zealand have been raised as
hypotheses. Perhaps surprisingly, Shiga toxin-producing
strains of Escherichia coli have emerged relatively recently,
but the incidence is now rising rapidly (30). One factor that
may contribute to the delayed appearance of this pathogen
may be New Zealand's system of pastoral agriculture. Cattle
and dairy herds graze year round in open fields, and there is
virtually no use of contained feedlots.
New Zealand has a growing aquaculture industry par-
ticularly focused on the cultivation of green-lipped mussels
(Perna canaliculus). As is the case in most temperate regions
where commercial shellfish cultivation occurs, nonbacterial
forms of seafood poisoning present a potential threat to the
industry and human health. A well-developed program of
environmental monitoring for dinoflagellate blooms provides
an early warning system that prevents potentially toxic
shellfish from entering the food chain (31).
Antimicrobial Resistance
Some global infectious disease threats tend to emerge
later in New Zealand than in most other industrialized coun-
tries. Delayed occurrence also applies to problems of antimi-
crobial resistance. One notable exception was the early
recognition in 1988 in Auckland of community-acquired
methicillin-resistant  Staphylococcus aureus (MRSA) infec-
tion. The relatively susceptible Western Samoan phage pat-
terns predominated (32,33). Multiple drug-resistant MRSA
strains remain relatively uncommon, particularly in South
Island, where routine screening of staff and patients fromPerspectives
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areas with endemic MRSA is still an effective hospital infec-
tion control practice.
The first vancomycin-resistant Enterococcus isolated in
New Zealand was reported from Waikato Hospital in 1996.
Studies confirm that vancomycin-resistant E. faecium and E.
faecalis are rare (34). The rate of sterile-site isolation of pen-
icillin-nonsusceptible Streptococcus pneumoniae was as low
as 2.0% in 1993 but rose to 15.1% in 1999. Multiple drug-
resistant tuberculosis is very rare and is exclusively
imported (35).
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The disease threats described above are likely to persist
unless effective control measures are introduced. In some
cases, (e.g., enteric diseases), more research is needed to
identify effective prevention and control measures. More
often, the measures are well defined but require the political
will and resources to introduce them, e.g., to raise immuniza-
tion coverage, create an environment that encourages safer
sexual practices, and address such social determinants as
overcrowding. Other disease threats are less predictable and
may be caused by the emergence of new organisms, changes
of known organisms, and the introduction of previously
absent organisms.
Emergence of New Organisms
To date, human pathogens found in New Zealand have
been identified elsewhere. A possible exception is a rickett-
sial disease first reported from North Island in the 1990s
(36,37). Cases were often reported in possum hunters and
clustered around the Kaukapakapa region. The rickettsial
species, yet to be determined, is probably from the typhus
group and may be transmitted to humans from Australian
brush-tailed possums by a flea vector. The implication of
these animals as a reservoir of an emerging rickettsial dis-
ease would only add to the spectra of infectious disease prob-
lems and environmental damage that some exotic mammals
cause. New Zealand expends considerable resources in pest
control.
Travel and Risk for Imported Diseases
New Zealanders have among the highest per capita
international travel rates in the world. Recent data suggest
a short-term annual departure rate of 0.31 per capita (38).
This compares with 0.22 per capita for Australia and 0.05
per capita for the United States. Oceania and Asia represent
the two most popular short-term travel destinations. In addi-
tion, New Zealand accepts in excess of 50,000 immigrants
annually, predominantly from the same regions. These
highly mobile populations provide an ongoing risk for impor-
tation of exotic disease. Some of these diseases are capable of
becoming established in New Zealand.
Vector-Borne Disease
No cases of vector-borne disease transmission within
New Zealand have been identified. Arboviruses are present,
but indigenous circulation of an arbovirus that causes dis-
ease in humans has not been documented. The Sindbis-like
alphavirus, Whataroa virus, is established in bird popula-
tions on the west coast of South Island, where human infec-
tion without disease has been determined (39,40). The
unclassified tick-borne arbovirus, Johnston Atoll virus, has
been documented in gannet colonies (41).
The potential for introduction of arboviruses currently
absent from New Zealand poses an important public health
threat (42). The greatest threat is from Australia, a nation
with a high incidence of arboviral disease and frequent trav-
eler exchange with New Zealand. Travelers viremic with
Ross River virus (RRV) and Dengue virus arrive with some
frequency in New Zealand. Competent exotic vector mosqui-
toes for both these viruses (i.e., A. notoscriptus, A. australis,
and  C. quinquefasciatus) are now established in New
Zealand. The efficient RRV vector, A. camptorhynchus (the
southern salt-marsh mosquito), was also recently introduced
from Australia (43). A. albopictus, a competent dengue vec-
tor, was detected in tires imported from Japan in 1993. This
cold-hardy mosquito has not become established in New
Zealand but could pose a threat in the future. For climatic
reasons, A. aegypti is probably precluded from New Zealand,
except for the extreme north. C. annulirostris from Australia
(vector of Murray Valley encephalitis virus) and  A. polyne-
siensis from the Pacific are vectors of RRV and would be of
concern if introduced into New Zealand. Furthermore, a low
level of community awareness of and involvement in mos-
quito control caused by the traditional absence of these dis-
eases would compound the public health effort required to
control outbreaks (42).
Conclusions and Global Relevance
New Zealand provides a unique model for the study of
emerging infectious diseases because of its unusual and
sparse indigenous fauna, geographic isolation, and relatively
recent exposure to humans and exotic animals. Although
zoonoses have provided and continue to provide disease con-
trol challenges, the economic and structural capacity of New
Zealand has allowed several diseases to be eliminated or con-
trolled. Strict agricultural quarantine practices have pre-
vented the reintroduction of these and other zoonotic
diseases and helped control human disease. New Zealand’s
facilities reflect the capacity and limitations of a quarantine
system functioning under near optimal circumstances and
illustrate the vulnerability of even this system to biocriminal
acts. Leptospirosis and bovine tuberculosis provide ongoing
challenges.
Group A streptococcal disease, staphylococcal disease,
meningococcal disease, and enteric infections are of particu-
lar importance in New Zealand; disparities in disease inci-
dence between ethnic groups are of concern. The reason for
the high incidence of these infections is being investigated.
These and other key communicable disease indicators sug-
gest that further investments in research and control are
warranted. A rickettsial disease, probably of the typhus
group, is currently emerging in New Zealand. Vectors are
established that are capable of transmitting a number of
anthropod-borne infections present in neighboring regions
and pose a threat should the organisma be imported. Other
infectious diseases consistently emerge up to 10 years later
in New Zealand than in other industrialized nations. Among
these are Shiga toxin-producing strains of  Escherichia coli
and a number of multidrug-resistant bacteria. Here, New
Zealand is in the unique position of being able to test recom-
mendations already established in other countries, relatively
early in an epidemic. Perspectives
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Although New Zealand invests considerable resources in
preventing the introduction of exotic animal and plant dis-
eases, human communicable disease control and research
have been inadequately supported. This can be attributed in
part to economic constraints and policy but also to compla-
cency that may have arisen from the country’s ecologically
privileged status for many infectious diseases. 
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